leisure time -WSS

leisure time

author：leisure time 2025-09-27 15:00:09 - browse：5

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

WSS

Medicare to pay more for cardiac rehab in hospital outpatient clinics

What happened to the House vote on health price transparency?

Senate bill would ban some hospital facility fees

SEC charges former device maker CEO with $41 million fraud

FDA weighs limits of animal data in assessing artificial wombs

Fed up with FDA, ALS advocates consider a take

focus

leisure time

Wikipedia

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Medicare Advantage beneficiaries sue Humana over algorithm use

Peter Hotez and the public health issue of online harassment

What STAT readers think about the FDA and patient advocacy

United colonoscopy coverage change 'may cost lives,' doctors say

Why the quest to eradicate polio has stumbled

Medicare proposal to cover medical devices draws a mixed reaction

Medicare Advantage beneficiaries sue Humana over algorithm use

Trump demands the U.S. pay no more for drugs than other countries … again

Medicare to pay more for cardiac rehab in hospital outpatient clinics

hotspot

Three trends to watch in biotech in 2024

SNAP should offer more nutrition education

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

SNAP should offer more nutrition education

'A game

The unintended consequences of overturning Roe v. Wade

entertainment

knowledge

hotspot

leisure time